MASLD, just my guess. On Oct 27 I cryptically posted "Embracing MASLD" upon stumbling onto a tie to the change in naming convention and an Enanta employee. There are also year 2022 and year 2023 enanta patent applications US and world wide for molecules relating to inhibitors of metabolic diseases. I am not certain the GLP-1 specifically is the target.
Market Data 
Markets 
AI
